skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: NTP-CERHR expert panel report on the reproductive anddevelopmental toxicity of hydroxyurea

Abstract

The National Toxicology Program (NTP) and the National Institute of Environmental Health Sciences (NIEHS) established the NTP Center for the Evaluation of Risks to Human Reproduction (CERHR) in June 1998. The purpose of CERHR is to provide timely, unbiased, scientifically sound evaluations of human and experimental evidence for adverse effects on reproduction and development caused by agents to which humans may be exposed. Hydroxyurea was selected for evaluation by a CERHR expert panel because of (1) its increasing use in the treatment of sickle cell disease in children and adults, (2) knowledge that it inhibits DNA synthesis and is cytotoxic, and (3) published evidence of its reproductive and developmental toxicity in rodents. Hydroxyurea is FDA-approved for reducing the frequency of painful crises and the need for blood transfusions in adults with sickle cell anemia who experience recurrent moderate-to-severe crises. Hydroxyurea is used in the treatment of cancer, sickle cell disease, and thalassemia. It is the only treatment for sickle cell disease aside from blood transfusion used in children. Hydroxyurea may be used in the treatment of children and adults with sickle cell disease for an extended period of time or for repeated cycles of therapy. Treatment with hydroxyurea may bemore » associated with cytotoxic and myelosuppressive effects, and hydroxyurea is mutagenic.« less

Authors:
; ; ; ; ; ; ; ; ; ; ; ;
Publication Date:
Research Org.:
COLLABORATION - U.Alabama
Sponsoring Org.:
USDOE
OSTI Identifier:
919398
Report Number(s):
LBNL-63404
TRN: US200822%%274
DOE Contract Number:
DE-AC02-05CH11231
Resource Type:
Journal Article
Resource Relation:
Journal Name: Birth Defects Research Part B; Journal Volume: 80; Related Information: Journal Publication Date: 2007
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES; ADULTS; BLOOD; CHILDREN; DISEASES; DNA; EVALUATION; HYDROXYUREA; NEOPLASMS; REPRODUCTION; RODENTS; SICKLE CELL ANEMIA; SYNTHESIS; THALASSEMIA; TOXICITY; TRANSFUSIONS

Citation Formats

Liebelt, E.L., Balk, S.J., Faber, W., Fisher, J.W., Hughes, C.L., Lanzkron, S.M., Lewis, K.M., Marchetti, F., Mehendale, H.M., Rogers,J.M., Shad, A.T., Skalko, R.G., and Stanek, E.J. NTP-CERHR expert panel report on the reproductive anddevelopmental toxicity of hydroxyurea. United States: N. p., 2007. Web. doi:10.1002/bdrb.20123.
Liebelt, E.L., Balk, S.J., Faber, W., Fisher, J.W., Hughes, C.L., Lanzkron, S.M., Lewis, K.M., Marchetti, F., Mehendale, H.M., Rogers,J.M., Shad, A.T., Skalko, R.G., & Stanek, E.J. NTP-CERHR expert panel report on the reproductive anddevelopmental toxicity of hydroxyurea. United States. doi:10.1002/bdrb.20123.
Liebelt, E.L., Balk, S.J., Faber, W., Fisher, J.W., Hughes, C.L., Lanzkron, S.M., Lewis, K.M., Marchetti, F., Mehendale, H.M., Rogers,J.M., Shad, A.T., Skalko, R.G., and Stanek, E.J. Mon . "NTP-CERHR expert panel report on the reproductive anddevelopmental toxicity of hydroxyurea". United States. doi:10.1002/bdrb.20123.
@article{osti_919398,
title = {NTP-CERHR expert panel report on the reproductive anddevelopmental toxicity of hydroxyurea},
author = {Liebelt, E.L. and Balk, S.J. and Faber, W. and Fisher, J.W. and Hughes, C.L. and Lanzkron, S.M. and Lewis, K.M. and Marchetti, F. and Mehendale, H.M. and Rogers,J.M. and Shad, A.T. and Skalko, R.G. and Stanek, E.J.},
abstractNote = {The National Toxicology Program (NTP) and the National Institute of Environmental Health Sciences (NIEHS) established the NTP Center for the Evaluation of Risks to Human Reproduction (CERHR) in June 1998. The purpose of CERHR is to provide timely, unbiased, scientifically sound evaluations of human and experimental evidence for adverse effects on reproduction and development caused by agents to which humans may be exposed. Hydroxyurea was selected for evaluation by a CERHR expert panel because of (1) its increasing use in the treatment of sickle cell disease in children and adults, (2) knowledge that it inhibits DNA synthesis and is cytotoxic, and (3) published evidence of its reproductive and developmental toxicity in rodents. Hydroxyurea is FDA-approved for reducing the frequency of painful crises and the need for blood transfusions in adults with sickle cell anemia who experience recurrent moderate-to-severe crises. Hydroxyurea is used in the treatment of cancer, sickle cell disease, and thalassemia. It is the only treatment for sickle cell disease aside from blood transfusion used in children. Hydroxyurea may be used in the treatment of children and adults with sickle cell disease for an extended period of time or for repeated cycles of therapy. Treatment with hydroxyurea may be associated with cytotoxic and myelosuppressive effects, and hydroxyurea is mutagenic.},
doi = {10.1002/bdrb.20123},
journal = {Birth Defects Research Part B},
number = ,
volume = 80,
place = {United States},
year = {Mon Jan 01 00:00:00 EST 2007},
month = {Mon Jan 01 00:00:00 EST 2007}
}